New hope for protecting kids from tuberculosis

NCT ID NCT07124559

Not yet recruiting Prevention Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

Summary

This study aims to find the safest and most effective dose of a 28-day medicine combination to prevent tuberculosis (TB) in children under 13 years old. It will include up to 144 children, both with and without HIV, who are at risk of getting TB. Researchers will closely monitor how the children's bodies process the medicine and check for any side effects over 24 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Baylor-Uganda (Site ID: 31798)

Kampala, Uganda
Chiangrai Prachanukroh Hospital (Site ID: 5116)

Chiang Rai, 57000, Thailand
Gaborone (Site ID: 12701)

Gaborone, Botswana
Harare Family Care (Site ID: 31890)

Belgravia, Harare, Zimbabwe
Kenya Medical Research Institute, Walter Reed Project Clinical Research Center (Site ID: 5121)

Kericho, 20200, Kenya
Les Centres GHESKIO (Site ID: 30022)

Port-au-Prince, HT-6110, Haiti
MU-JHU Care Limited (Site ID: 5126)

Kampala, Uganda
Molepolole (Site ID: 12702)

Gaborone, Botswana
Seke North (Site ID: 30306)

Belgravia, Harare, Zimbabwe
Siriraj Hospital, Mahidol University (Site ID: 5115)

Bangkok, Bangkoknoi, 10700, Thailand
St Mary's (Site ID: 30303)

Chitungwiza, Zimbabwe

Conditions

Explore the condition pages connected to this study.

TUBERCULOSIS